Zobrazeno 1 - 10
of 422
pro vyhledávání: '"Cryptophycin 52"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Leena Hussein Bajrai; Special Infectious Agents Unit, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia. lbajrai@kau.edu.sa., Sayed Sartaj Sohrab; Special Infectious Agents Unit, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia. sayedsartaj@gmail.com., Mohammad Khalid; Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi Arabia. drkhalid8811@gmail.com., Mohammad A Kamal; Special Infectious Agents Unit, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia. prof.ma.kamal@gmail.com., Esam Ibraheem Azhar; Special Infectious Agents Unit, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia. eazhar@kau.edu.sa.
Publikováno v:
Cellular and molecular biology (Noisy-le-Grand, France) [Cell Mol Biol (Noisy-le-grand)] 2022 Jun 30; Vol. 68 (6), pp. 31-35. Date of Electronic Publication: 2022 Jun 30.
Autor:
null Leena Hussein Bajrai, null Sayed Sartaj Sohrab, null Mohammad Khalid, null Mohammad A. Kamal, null Esam Ibraheem Azhar
Publikováno v:
Cellular and molecular biology (Noisy-le-Grand, France). 68(6)
It has been seen that, during COVID-19 outbreak lung cancer (LC) patients are noted as a high-risk population which make a more challenging to treatment of the LC patients. The active form of caspase-8 is involved in lung carcinogenesis in both human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::969a064ea2c0de7b58b035ad143aa821
https://pubmed.ncbi.nlm.nih.gov/36227681
https://pubmed.ncbi.nlm.nih.gov/36227681
Autor:
Edelman, Martin J *, Gandara, David R, Hausner, Petr, Israel, Valerie, Thornton, Donald, DeSanto, Jennifer, Doyle, L.Austin
Publikováno v:
In Lung Cancer 2003 39(2):197-199
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Richard M. Schultz, Joseph H. Kennedy, Rima S. Al-Awar, Gottumukkala V. Subbaraju, Jian Liang, Thomas H. Corbett, Richard E. Moore, James E. Ray, Sherri L. Andis, Trimurtulu Golakoti
Publikováno v:
Journal of Medicinal Chemistry. 46:2985-3007
Cryptophycin 52 is a synthetic derivative of Cryptophycin 1, a potent antimicrotubule agent isolated from cyanobacteria. In an effort to increase the potency and water solubility of the molecule, a structure-activity relationship study (SAR) was init
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aea75cbc5fbe1eec811d06b06b062daf
https://doi.org/10.1021/jm0203884
https://doi.org/10.1021/jm0203884
Autor:
David Kessel
Publikováno v:
Journal of Chromatography B: Biomedical Sciences and Applications. 735:121-126
Exposure of murine leukemia L1210 cells to the antitumor antibiotic cryptophycin 52 (C52) resulted in a rapid and dose-dependent increase in cell-surface hydrophobicity, as measured with a two-phase partitioning system. This effect was not observed w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da852cb887910761c67fcba7179b8704
https://doi.org/10.1016/s0378-4347(99)00404-1
https://doi.org/10.1016/s0378-4347(99)00404-1
Autor:
Jian Liang, Moher, Eric D.
Publikováno v:
Journal of Organic Chemistry; 05/19/2000, Vol. 65 Issue 10, p3143, 5p, 4 Diagrams, 1 Chart
Autor:
Jennifer DeSanto, Petr F. Hausner, David R. Gandara, Martin J. Edelman, Donald Thornton, Valerie Israel, L. Austin Doyle
Publikováno v:
Lung Cancer. 39:197-199
Background: Cryptophycin 52 is a novel antitubulin drug with in vitro and in vivo activity in non-small cell lung cancer. Based upon promising Phase 1 data, a multicenter trial was performed to evaluate the drug in previously treated non-small cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9637b61eb81f40ad926fd931fc50131
https://doi.org/10.1016/s0169-5002(02)00511-1
https://doi.org/10.1016/s0169-5002(02)00511-1